ATE303162T1 - Natrium kanalblocker zusammensetzungen und deren verwendung - Google Patents

Natrium kanalblocker zusammensetzungen und deren verwendung

Info

Publication number
ATE303162T1
ATE303162T1 AT00923183T AT00923183T ATE303162T1 AT E303162 T1 ATE303162 T1 AT E303162T1 AT 00923183 T AT00923183 T AT 00923183T AT 00923183 T AT00923183 T AT 00923183T AT E303162 T1 ATE303162 T1 AT E303162T1
Authority
AT
Austria
Prior art keywords
sodium channel
channel blocking
blocking compositions
convulsion
disclosed
Prior art date
Application number
AT00923183T
Other languages
English (en)
Inventor
Nancy C Lan
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE303162T1 publication Critical patent/ATE303162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00923183T 1999-04-09 2000-04-10 Natrium kanalblocker zusammensetzungen und deren verwendung ATE303162T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12854399P 1999-04-09 1999-04-09
PCT/US2000/009387 WO2000061188A1 (en) 1999-04-09 2000-04-10 Sodium channel blocker compositions and the use thereof

Publications (1)

Publication Number Publication Date
ATE303162T1 true ATE303162T1 (de) 2005-09-15

Family

ID=22435837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923183T ATE303162T1 (de) 1999-04-09 2000-04-10 Natrium kanalblocker zusammensetzungen und deren verwendung

Country Status (9)

Country Link
US (3) US20020037926A1 (de)
EP (1) EP1169060B1 (de)
JP (1) JP2002541215A (de)
AT (1) ATE303162T1 (de)
AU (1) AU4334900A (de)
CA (1) CA2370030C (de)
DE (1) DE60022333T2 (de)
DK (1) DK1169060T3 (de)
WO (1) WO2000061188A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SI1423168T1 (sl) * 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
BRPI0200751B1 (pt) * 2002-02-06 2018-10-23 Univ Minas Gerais complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação
WO2003072751A2 (en) 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
CN101862317A (zh) * 2002-12-13 2010-10-20 沃尼尔·朗伯有限责任公司 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
EP1438956A1 (de) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
DE10359335A1 (de) * 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
US20050112183A1 (en) * 2003-11-25 2005-05-26 Galer Bradley S. Compositions and methods for treating neuropathic sensory loss
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
CA2590962A1 (en) * 2004-12-06 2006-06-15 Siga Technologies, Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US8410149B2 (en) 2004-12-06 2013-04-02 Siga Technologies Inc. Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US7994221B2 (en) 2004-12-06 2011-08-09 Siga Technologies, Inc. Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP1963280B1 (de) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CN101034257B (zh) * 2007-04-06 2010-09-08 上海复旦天臣新技术有限公司 用于全息记录的感光薄膜及其制备方法
US20100249238A1 (en) * 2007-07-02 2010-09-30 Ruben Dario Sinisterra Pharmaceutical compositions comprising semicarbazones and thiosemicarbazones and method for treating inflammatory, painful and febrile conditions and preventing signs and symptoms of inflammation
EP2219633A2 (de) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol-zusammensetzungen
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20110184337A1 (en) * 2010-01-26 2011-07-28 Evans Michael A Methods and devices for denervation
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2616441B1 (de) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridinverbindungen und ihre verwendung
AU2011311238A1 (en) 2010-10-05 2013-04-04 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
WO2012048294A2 (en) * 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
JP2014500303A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としての置換ピリジン
AU2012300567B2 (en) 2011-09-02 2016-03-10 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
AU2012324010A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
WO2014112152A1 (ja) 2013-01-18 2014-07-24 有限会社ケムフィズ 神経因性疾病の治療のための医薬
AU2014224310B2 (en) 2013-03-04 2017-02-09 Purdue Pharma L.P. Pyrimidine carboxamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA3082427A1 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
CA2922567A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
AU2014370407B2 (en) 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (de) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridonsulfonmorphinan-analoga als opioidrezeptorliganden
WO2015112801A1 (en) 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
AU2015217185B2 (en) 2014-02-12 2018-04-05 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US9975854B2 (en) 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
EP3761036B1 (de) * 2015-03-03 2025-11-19 ARK Diagnostics, Inc. Pregabalinimmunoassays
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
EP4297741A4 (de) * 2021-02-26 2025-02-26 Vyluma Inc. Verfahren und formulierungen zur topischen verabreichung von gabapentinoiden
CN115554293A (zh) * 2021-07-01 2023-01-03 南京宁丹新药技术有限公司 一种药物组合物及其用途
CN117482071A (zh) * 2023-11-10 2024-02-02 浙江震元制药有限公司 右旋莰醇在制备增强γ-氨基丁酸类药物镇痛作用的产品中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US549692A (en) * 1895-11-12 And albert s
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
EP0021121B1 (de) 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-Triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und sie enthaltende pharmazeutische Zusammensetzungen
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
GB9306899D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
CA2264182A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
AU4031697A (en) 1996-08-29 1998-03-19 Takeda Chemical Industries Ltd. Cyclic ether compounds as sodium channel modulators
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
WO1998019674A2 (en) 1996-11-05 1998-05-14 Head Explorer Aps A method for treating tension-type headache
US6207685B1 (en) 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
FR2756738B1 (fr) * 1996-12-06 1999-02-12 Sod Conseils Rech Applic Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
GB9706730D0 (en) 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
WO1998047869A1 (en) * 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
EP1011658B1 (de) * 1997-09-08 2005-12-07 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
DE19802327A1 (de) 1998-01-23 1999-07-29 Goedecke Ag Synergistische Arzneimittelzubereitung mit analgetischer Wirkung
WO1999037296A1 (en) 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US5905069A (en) 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
EP1058550A4 (de) 1998-02-04 2002-12-18 Euro Celtique Sa Substituierte semicarbazide und deren verwendung
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
JP2002520286A (ja) 1998-07-09 2002-07-09 ワーナー−ランバート・カンパニー Ｇａｂａ類縁体及びカフェインを含んでなる組成物
ATE279188T1 (de) 1998-07-09 2004-10-15 Warner Lambert Co Pharmazeutische zusammensetzungen enthaltend gaba-analogen und ein antivirales mittel zur behandlung von herpes zoster
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
ES2345921T3 (es) 1999-03-26 2010-10-06 Euro-Celtique S.A. Pirazoles, imidazoles, oxazoles, tiazoles y pirroles sustituidos con arilo y su uso.
WO2000061188A1 (en) * 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba

Also Published As

Publication number Publication date
US20080318932A1 (en) 2008-12-25
US7393872B2 (en) 2008-07-01
EP1169060B1 (de) 2005-08-31
DE60022333T2 (de) 2006-07-06
WO2000061188A9 (en) 2002-02-14
US20040054005A1 (en) 2004-03-18
DK1169060T3 (da) 2006-01-16
JP2002541215A (ja) 2002-12-03
AU4334900A (en) 2000-11-14
DE60022333D1 (de) 2005-10-06
CA2370030A1 (en) 2000-10-19
CA2370030C (en) 2007-08-14
EP1169060A1 (de) 2002-01-09
WO2000061188A1 (en) 2000-10-19
US20020037926A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DE60022333D1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
IS5890A (is) Aðferð til að gefa sýklalyf
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
EA200101240A1 (ru) Использование мелатонина в медицине
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
DK1140103T3 (da) Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia
PT1056458E (pt) Tratamento de dor cronica
AU5434899A (en) Cancer treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169060

Country of ref document: EP